Physician profile
Eric Steinberg
NPI 1316933054
$2,673.82
in general payments reported to CMS, 2019-2025
25 companies · $28.22 in 2025
The $28.22 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.89 · 2020: $178 · 2021: $760 · 2022: $720 · 2023: $522 · 2024: $388 · 2025: $28.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.98 | 2019-2024 | Skyrizi, Mavyret, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $621.19 | 2020-2024 | Trulance, Xifaxan, Relistor |
| Janssen Biotech, INC. | $260.01 | 2021-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $136.57 | 2021-2024 | Entyvio |
| Pfizer INC. | $117.63 | 2019-2021 | |
| Gilead Sciences, INC. | $106.79 | 2020-2023 | Epclusa |
| Nestle Healthcare Nutrition INC. | $92.87 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $78.17 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $57.23 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $55.02 | 2022 | |
| Alnylam Pharmaceuticals INC. | $38.00 | 2020-2021 | |
| Allergan, INC. | $35.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $35.56 | 2024 | |
| Genzyme Corporation | $31.91 | 2023 | |
| Celgene Corporation | $30.69 | 2022-2024 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $26.30 | 2021-2022 | |
| Thd America, INC. | $25.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.49 | 2024 | Ofev |
| Medtronic, INC. | $19.63 | 2022 | |
| Baxter Healthcare | $18.99 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Olympus America INC. | $17.40 | 2023 | Endoclot Phs, Single Use Grasping Forceps |
| Aimmune Therapeutics, INC. | $14.60 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $14.41 | 2022 | |
| Madrigal Pharmaceuticals | $13.62 | 2025 | Rezdiffra |
| Romark Laboratories, Lc | $6.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.